{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.42","value":"4.6"}]}],"title":"Alanine Aminotransferase"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.22","value":"-3.9"}]}],"title":"Aspartate Aminotransferase"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"339.82","value":"-138.2"}]}],"title":"Lactate Dehydrogenase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Change from baseline in Chemistry laboratory analysis. Includes Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase. Baseline is the last observation collected prior to or on the date of product infusion.","dispersionType":"Standard Deviation","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"MEAN","populationDescription":"All participants who received at least one JCAR017 infusion evaluable for chemistry laboratory tests","reportingStatus":"POSTED","timeFrame":"Baseline and Day 29","title":"Change From Baseline of Chemistry Laboratory Results: Alanine Aminotransferase, Aspartate Aminotransferase, Lactate Dehydrogenase","type":"SECONDARY","unitOfMeasure":"U/L"}